Evolution of Treatment Strategies Targeting IL-23 for Psoriasis

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Overview of the Pathogenesis and Treatment of Psoriasis

Evolution in the Understanding of the Pathogenesis of Psoriasis

Role of IL-23/IL-17 Axis as the Main Pathogenetic Pathway in Psoriasis

Key Targets and Development of Immunotherapies: Regulatory Approval

Key Targets and Development of Immunotherapies: EMA Approvals

Challenges and Limitations of IL-17 Agents Despite High Efficacy

Structure of p40 Cytokines and Targeted Agents

Advantages of Blocking IL-23

Guselkumab vs Adalimumab: VOYAGE 1 Study

Patient-Reported Improvements in HRQoL in VOYAGE 1

VOYAGE 1: Data for 2 Years of Exposure to Guselkumab and Nonresponder Imputation

Guselkumab Maintenance and Withdrawal: VOYAGE 2

Guselkumab in Patients With Inadequate Response to Ustekinumab: NAVIGATE

Other IL-23p19 Inhibitors in the Pipeline

Tildrakizumab: reSURFACE 1 and reSURFACE 2

Safety of Biologics for Psoriasis

Safety of Biologics for Psoriasis: Infections and IBD

Advantages of Selective IL-23 Inhibition: Clinical Considerations

Limitations of Selective IL-23 Inhibition: Areas for Further Investigation

Clinician Perspectives on Use of Selective IL-23 Inhibitors

Low Incidence of Serious Infections After 2 Years of Exposure to Selective IL-23 Inhibition

Clinician Perspectives on Real-World Use of Guselkumab

Concluding Remarks

Abbreviations

Abbreviations (cont)